Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting
September 21, 2022 08:34 ET
|
Helsinn Healthcare S.A.
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both clinical trials and real-world settings will be presentedHelsinn...
Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care
September 08, 2022 08:00 ET
|
Helsinn Healthcare S.A.
Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care Lugano, Switzerland, September 8, 2022 - Helsinn Group...
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
September 01, 2022 05:08 ET
|
Helsinn Healthcare S.A.
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East* Lugano, Switzerland, September 1, 2022 –...
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer
August 08, 2022 04:07 ET
|
Helsinn Healthcare S.A.
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022
June 02, 2022 08:30 ET
|
Helsinn Healthcare S.A.
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022 Lugano, Switzerland, June 02, 2022 - Helsinn Group (“Helsinn”), a fully...
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy
May 25, 2022 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.),...
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
May 19, 2022 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of...
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference
May 11, 2022 07:00 ET
|
Helsinn Healthcare S.A.
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference Lugano, Switzerland, May 11, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with...
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets
May 04, 2022 02:00 ET
|
Helsinn Healthcare S.A.
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* Lugano, Switzerland, and Singapore, 04 May 2022 – Juniper Biologics Pte Ltd , a...
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan
March 28, 2022 04:15 ET
|
Helsinn Healthcare S.A.
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan Tokyo, Japan, and Lugano, Switzerland March 28, 2022 - Taiho...